Cargando…

A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

Significant progress has been achieved in treating patients with onco-hematological diseases, including chronic myeloid leukemia (CML). This is primarily associated with the development of targeted therapy involving tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, dasatinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopina, Nataliia, Dmytrenko, Iryna, Hamov, Dmytro, Lopin, Dmytro, Dyagil, Iryna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270100/ https://www.ncbi.nlm.nih.gov/pubmed/35812557 http://dx.doi.org/10.7759/cureus.25766

Ejemplares similares

Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury
por: Lopina, Nataliia, et al.
Publicado: (2019)

Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis
por: Lopina, Nataliia, et al.
Publicado: (2018)

Extramedullary Acute Myeloid Leukemia Presenting With Pericardial Effusion and Arrhythmias
por: Najam, Usman S, et al.
Publicado: (2023)

P590: MODIFICATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UKRAINIAN PROSPECTIVE STUDY IN A REAL-LIFE COHORT.
por: Stupakova, Zinaida, et al.
Publicado: (2023)

An Interesting Case of Serratia Endocarditis in a Patient With Chronic Myeloid Leukemia
por: Singh, Annapoorna, et al.
Publicado: (2022)

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
por: Soverini, Simona, et al.
Publicado: (2018)

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
por: Kronick, Olivia, et al.
Publicado: (2023)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Cardio-Thyrotoxicosis Syndrome: A Review of Thyrotoxic Cardiovascular Disease
por: Bhattad, Pradnya Brijmohan, et al.
Publicado: (2023)

Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia
por: Moursy, Safa, et al.
Publicado: (2020)

Cardiovascular Complications Secondary to Graves’ Disease: A Prospective Study from Ukraine
por: Tsymbaliuk, Iryna, et al.
Publicado: (2015)

Acute Myocardial Infarction as Initial Manifestation of Acute Myeloid Leukemia: A Rare Manifestation of Leukostasis
por: Manogna, Dharmini, et al.
Publicado: (2020)

His-optimized cardiac resynchronization therapy in a patient with heart failure and right bundle branch block: a case report
por: Volkov, Dmytro, et al.
Publicado: (2021)

Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib
por: Papaila, Alexa, et al.
Publicado: (2021)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan, Bee Kim, et al.
Publicado: (2021)

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia
por: Eiring, Anna M, et al.
Publicado: (2014)

Heart’s Dangerous Symphony: Torsade De Pointes Unleashed by Gitelman Syndrome-Induced Hypomagnesemia
por: Idries, Iyad Y, et al.
Publicado: (2023)

WITHDRAWN: Current aspects of vaccination against Covid-19 under conditions of war in Ukraine: Problems and prospects
por: Korolchuk, Olena, et al.
Publicado: (2023)

COVID-19 Vaccination under Conditions of War in Ukraine
por: Korolchuk, Olena, et al.
Publicado: (2023)

Cardio-oncology Clinical Assessment and Screening in Patients Undergoing High Toxicity Chemotherapy: A Retrospective Cohort Study
por: Regino, Carlos A, et al.
Publicado: (2022)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Zofenopril: Blood pressure control and cardio-protection
por: Borghi, Claudio, et al.
Publicado: (2022)

Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients
por: Yang, Bingyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qu4t94n6cmcs3um4m939bea0hb